FDA Approves First Orexin Agonist, ORZEYFUL, for Narcolepsy Type 1

The FDA has approved ORZEYFUL (oveporexton), making it the first orexin agonist available for adults with narcolepsy type 1. This represents a significant advancement in neuroscience and sleep medicine, as the drug directly targets the underlying biological cause of the condition by restoring orexin signaling.